Abcam (LSE:ABC) Common Stock : £0.5 Mil (As of Jun. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Abcam Common Stock?

Abcam's quarterly common stock stayed the same from Jun. 2022 (£0.5 Mil) to Dec. 2022 (£0.5 Mil) and stayed the same from Dec. 2022 (£0.5 Mil) to Jun. 2023 (£0.5 Mil).

Abcam's annual common stock stayed the same from Jun. 2019 (£0.4 Mil) to Jun. 2020 (£0.4 Mil) but then increased from Jun. 2020 (£0.4 Mil) to Dec. 2022 (£0.5 Mil).

Abcam Common Stock Historical Data

The historical data trend for Abcam's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam Common Stock Chart

Abcam Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec22

Common Stock

Get a 7-Day Free Trial

0.40

0.50

Abcam Semi-Annual Data
	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Jun22	Dec22	Jun23
Common Stock	Get a 7-Day Free Trial															0.50	0.50	0.50	0.50	0.50

Abcam Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Abcam (LSE:ABC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (LSE:ABC) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX

Website

https://www.abcam.com

Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.

Abcam (LSE:ABC) Headlines

No Headlines